Frankfurt
03.12.25 | 18:07
0,086 Euro
+31,34 % +0,020
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,081 | 0,085 | 03.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Mauna Kea Technologies and TaeWoong Medical USA Announce Exclusive Partnership to Accelerate Commercial Expansion in the U.S. in Pancreatic Cyst Management | 220 | Business Wire | Integrating Cellvizio into TaeWoong's portfolio of therapeutic devices to create the first fully integrated "imaging-to-therapy" solution for EUS-guided pancreatic care
Regulatory News:
Mauna... ► Artikel lesen | |
| 20.11. | Mauna Kea Technologies Receives NMPA Regulatory Approval in China for its Next-Generation Cellvizio Platform | 376 | Business Wire | NMPA approval obtained following a 3-year certification process Mauna Kea is now evaluating options to commercialize Cellvizio Gen 3 in China independently of the JV with Tasly
Regulatory... ► Artikel lesen | |
| 17.11. | XFRA 1MK: WIEDERAUFNAHME/RESUMPTION | 183 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 14.11. | Mauna Kea Technologies: €6 Million Raised To Strengthen Long Term Growth | 2 | pulse2.com | ||
| 14.11. | Mauna Kea Technologies Announces the Successful Completion of Its Financial Restructuring and €6M Capital Raise | 422 | Business Wire | 70% debt write-off, from €40M to €12M Remaining debt to be repaid over 10 years, with 90% between the end of 2029 and the end of 2035 Capital raise of €6.1M extending cash runway to the second... ► Artikel lesen | |
| 13.11. | XFRA 1MK: AUSSETZUNG/SUSPENSION | 443 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMAUNA KEA TECHNOL.EO... ► Artikel lesen | |
| 13.11. | Mauna Kea Technologies Exits Safeguard Proceedings Following Court Approval of its Plan and Initiates Minimum €5M Capital Raise | 368 | Business Wire | Safeguard plan approved by judgment of the Paris Commercial Court on November 12, 2025 Launch of a reserved capital increase in the form of shares with attached warrants (ABSA) at a price of... ► Artikel lesen | |
| 06.11. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 268 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 21.10. | Mauna Kea Technologies Announces It Has Secured Over €5M in Firm Subscription Commitments as Required for Its Capital Increase | 414 | Business Wire | New equity financing would provide the Company sufficient financial visibility to execute its strategic plan and achieve profitability The future exercise of share subscription warrants (BSA)... ► Artikel lesen | |
| 13.10. | Mauna Kea Technologies Reports Third Quarter 2025 Revenue Up +16% at Constant Exchange Rates | 244 | Business Wire | U.S. sales surge +31% at constant exchange rates, with continued acceleration over the year Commercial momentum highlighted by a doubling of U.S. system sales year-to-date Adding to U.S. commercial... ► Artikel lesen | |
| 08.10. | Mauna Kea Technologies Announces the Terms of its Financing Under its Safeguard Plan | 553 | Business Wire | Capital increase of €5m to €8m through a private placement planned for the first half of November via the issuance of shares with attached warrants (ABSA) Firm commitment from an investor for... ► Artikel lesen | |
| 06.10. | Mauna Kea Technologies Reaches a Key Milestone in Its Financial Restructuring | 916 | Business Wire | A large majority of creditors and shareholders have voted in favor of the draft safeguard plan This plan includes a 70% reduction in debt, from €40 million to €12 million, with a payment schedule... ► Artikel lesen | |
| 02.10. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 353 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 01.10. | Mauna Kea Technologies Announces 2025 Half-Year Results | 341 | Business Wire | 32% Reduction in H1 2025 Current Operating Loss excluding [Non-cash] Share-based Payments Improvement Reflects Strict Expense Control and 17% U.S. Sales Growth1 Finalization of Safeguard Plan... ► Artikel lesen | |
| 22.09. | Mauna Kea Technologies Presents the Final Terms of its Safeguard Plan | 417 | Business Wire | Reduction of the Company's debt from €40 million to €12 million, spread over 10 years Capital increase of at least €5 million post-plan adoption, with the issuance of stock warrants (BSAs) to... ► Artikel lesen | |
| 18.09. | Mauna Kea Technologies and Endotherapeutics Announce Cellvizio First Australian Orders, Advancing CellTolerance Commercial Expansion | 588 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT) and Endotherapeutics, today announced that Cellvizio system has been included in the Australian Register of Therapeutic Goods... ► Artikel lesen | |
| 12.09. | Mauna Kea Technologies Unveils the Outlines of its Safeguard Plan to Ensure its Turnaround | 706 | Business Wire | Shareholders, holders of securities giving access to the capital, and creditors of Mauna Kea Technologies convened into classes of affected parties to vote on the safeguard plan
Regulatory News:... ► Artikel lesen | |
| 08.09. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 271 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 08.09. | Mauna Kea Technologies Announces Strong Advocacy from the American Foregut Society (AFS) for Broad Reimbursement Coverage from U.S. Commercial Payors for Cellvizio | 341 | Business Wire | New letter published by the AFS highlights Cellvizio's superiority to conventional tools for detecting pre-cancerous tissue and dysplasia
Regulatory News:
Mauna Kea Technologies (Euronext... ► Artikel lesen | |
| 29.08. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 567 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,087 | +0,58 % | Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 13, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH) ("Sernova or the Company)") a leading regenerative medicine... ► Artikel lesen | |
| FAMICORD | 5,300 | 0,00 % | EQS-News: FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung | EQS-News: FamiCord AG
/ Schlagwort(e): 9-Monatszahlen
FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung... ► Artikel lesen | |
| GERATHERM MEDICAL | 3,400 | +5,92 % | Geratherm Medical AG: Starkes Wachstum im ersten Halbjahr und operatives Break-even; KAUFEN bestätigt. | Geratherm verzeichnete im ersten Halbjahr 2025 ein starkes Wachstum: Die vergleichbaren Umsätze stiegen um 13,2 % gegenüber dem Vorjahr und sequenziell um 15,4 %. Getrieben wurde dieses Wachstum von... ► Artikel lesen | |
| PLUS THERAPEUTICS | 0,597 | +1,15 % | Plus Therapeutics to present breast cancer treatment data at SABCS | ||
| MEDICLIN | 3,560 | +4,09 % | EQS-AFR: MEDICLIN AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: MEDICLIN AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
MEDICLIN AG: Vorabbekanntmachung über die Veröffentlichung... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,615 | -3,15 % | Atossa Therapeutics Inc: Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma | CAMBRIDGE, Mass., Dec. 2, 2025 /PRNewswire/ -- Insilico Medicine ("Insilico"), a global leader in AI-powered drug discovery, and Atossa Therapeutics ("Atossa")... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,480 | -100,00 % | Sonoma Pharmaceuticals, Inc.: National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced | BOULDER, CO / ACCESS Newswire / November 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
| VERU | 2,420 | 0,00 % | Veru Inc.: Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress | --Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal... ► Artikel lesen | |
| LIFEWARD | 0,690 | 0,00 % | Lifeward Ltd. Reports Third Quarter 2025 Financial Results | Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27%... ► Artikel lesen | |
| LIGHT AI | 0,088 | -17,95 % | Light AI Inc: Light AI completes V1.0 diagnostic software system | ||
| MAVEN BRANDS | 0,001 | 0,00 % | Maven Brands Inc: Maven Brands to sell subdivided Lumby land for $3.5M | ||
| EKSO BIONICS | 4,350 | 0,00 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Third Quarter 2025 Financial Results | SAN RAFAEL, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,340 | -1,37 % | Neue 3,250%-Anleihe von Fresenius Medical Care | Stuttgart (www.anleihencheck.de) - Fresenius Medical Care (ISIN DE0005785802/ WKN 578580) hat eine Unternehmensanleihe (ISIN XS3233499089/ WKN A460DH) mit einem Volumen von bis zu 500 Millionen Euro... ► Artikel lesen | |
| FRESENIUS | 47,210 | +0,75 % | DZ BANK stuft Fresenius SE auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Aktienwert für Fresenius nach den Anfang November vorgelegten Zahlen zum dritten Quartal von 56 auf 57 Euro angehoben. Die Einstufung wurde... ► Artikel lesen |
Das Unternehmen MAUNA KEA TECHNOLOGIES kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,020 (+31,34 %) liegt der Kurs bei 0,086 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.